Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.

Toxicology and applied pharmacology 2023 Jan 15

filter terms:

The anthracyclines are a family of natural products isolated from soil bacteria with over 2000 chemical representatives. Since their discovery seventy years ago by Waksman and co-workers, anthracyclines have become one of the best-characterized anticancer chemotherapies in clinical use. The anthracyclines exhibit broad-spectrum antineoplastic activity for the treatment of a variety of solid and liquid tumors, however, their clinical use is limited by their dose-limiting cardiotoxicity. In this review article, we discuss the toxicity of the anthracyclines on several organ systems, including new insights into doxorubicin-induced cardiotoxicity. In addition, we discuss new medicinal chemistry developments in the biosynthesis of new anthracycline analogs and the synthesis of new anthracycline analogs with diminished cardiotoxicity. Lastly, we review new studies that describe the repurposing of the anthracyclines, or "upcycling" of the anthracyclines, as anti-infective agents, or drugs for niche indications. Altogether, the anthracyclines remain a mainstay in the clinic with a potential new "lease on life" due to deeper insight into the mechanism underlying their cardiotoxicity and new developments into potential new clinical indications for their use. Keywords: Anthracycline, chemotherapy, toxicology, medicinal chemistry, biosynthesis. Copyright © 2022 Elsevier Inc. All rights reserved.

Citation

Claudine E Bayles, Danielle E Hale, Ali Konieczny, Veronica D Anderson, Claire R Richardson, Katelyn V Brown, Jennifer T Nguyen, Jacob Hecht, Nora Schwartz, Madan K Kharel, Felix Amissah, Thomas C Dowling, S Eric Nybo. Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology. Toxicology and applied pharmacology. 2023 Jan 15;459:116362